1. Home
  2. SENEB vs CMPX Comparison

SENEB vs CMPX Comparison

Compare SENEB & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seneca Foods Corp. Class B

SENEB

Seneca Foods Corp. Class B

N/A

Current Price

$137.55

Market Cap

880.5M

ML Signal

N/A

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$1.96

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SENEB
CMPX
Founded
1949
2014
Country
United States
United States
Employees
6895
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
880.5M
927.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SENEB
CMPX
Price
$137.55
$1.96
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$14.57
AVG Volume (30 Days)
473.0
10.7M
Earning Date
06-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$934.41
P/E Ratio
$12.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$90.19
$1.61
52 Week High
$164.98
$6.88

Technical Indicators

Market Signals
Indicator
SENEB
CMPX
Relative Strength Index (RSI) 53.94 24.64
Support Level $131.45 N/A
Resistance Level $164.98 $3.74
Average True Range (ATR) 0.31 0.50
MACD -1.73 -0.42
Stochastic Oscillator 17.98 6.78

Price Performance

Historical Comparison
SENEB
CMPX

About SENEB Seneca Foods Corp. Class B

Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: